skip to main content

VarmX

Revolutionary treatment for bleedings in patients taking anticoagulants

VarmX is developing a treatment for severe bleeding in patients taking anticoagulants. The new treatment is based on administering a modified clotting protein that can stop or prevent bleeding in patients who need emergency surgery.

Mibiton is financing R&D equipment that can improve and further develop the production of the clotting protein.

Daniël Verhoef

"With the support of Mibiton, VarmX has been able to acquire high-end equipment that enables us to set up a small-scale version of our production process in our laboratory. This allows us to study and further optimize the process in detail before bringing our medicine to market."